Ipsen S.A.
PAR: IPN.PA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- David Loew
- Employees
- 5,358
- Headquarters
- Boulogne-Billancourt, France
- IPO year
- 2005
- Market cap
- €13.8B
- Website
- https://www.ipsen.com
Loading IPN…
Loading profile data…Frequently asked questions about IPN
What does Ipsen S.A. (IPN.PA) do?
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and...
Where does IPN.PA trade?
Ipsen S.A. (IPN.PA) trades on the Euronext Paris.
What sector is IPN.PA in?
Ipsen S.A. (IPN.PA) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Ipsen S.A.?
David Loew is the chief executive officer of Ipsen S.A. (IPN.PA).
Where is Ipsen S.A. headquartered?
Ipsen S.A. is headquartered in France.
Does IPN.PA pay a dividend?
Yes — Ipsen S.A. (IPN.PA) paid a trailing twelve-month dividend of EUR 1.40 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did IPN.PA go public?
Ipsen S.A. (IPN.PA) completed its initial public offering in 2005.